ArticleCurrent microbiology2025
Genomic Insights into Azole Resistance Mechanisms in Candida tropicalis Among Hematological Malignancy Patients with Candidemia.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Invasive candidiasis caused by Candida tropicalis poses a significant threat to patients with hematological malignancies. The increasing prevalence of azole resistance among C. tropicalis isolates complicates treatment strategies, necessitating a detailed understanding of the underlying resistance mechanisms. We conducted a genomic analysis of 15 C. tropicalis isolates collected from patients with hematological malignancies between 2017 and 2021. Whole-genome sequencing (WGS) was performed to obtain high-resolution genomic data. Three strains of C. tropicalis showed azole sensitivity in vitro susceptibility testing and the remaining 12 strains were azole resistant. MLST clade 4 emerged as the predominant azole-resistant clone. All azole-resistant isolates carried the ERG11 mutations A395T and C461T, and most carried the UPC2 mutation T503C. A consistent copy number variation (CNV) at the ERG11 locus was observed in all resistant isolates, suggesting its pivotal role in azole resistance. Our integrated analysis, including SNP, dN/dS ratio, and CNV, confirmed ERG11 as a central player in C. tropicalis' resistance mechanisms in the study. This study provides a comprehensive genomic analysis of azole-resistant C. tropicalis isolates from patients with hematological malignancies. The identification of key genomic alterations, particularly those in the ERG11 gene, offers valuable insights for clinical management and underscores the need for continuous resistant gene surveillance to guide antifungal stewardship in oncology settings.
Indexed as
Identifiers
41081941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.